AKRO Akero Therapeutics

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present at the following investor conferences this month:

  • Jefferies London Healthcare Conference: Fireside chat on Wednesday, November 15 at 5:00 p.m. GMT
  • Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, November 29 at 7:30 a.m. ET

Live webcasts of the Company presentations will be available through the investor relations section of the Company's website at . Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies. Akero's lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. EFX is currently being evaluated in two ongoing, 96-week Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Screening in the first two of three Phase 3 clinical trials began in September 2023, the SYNCHRONY Histology study and the SYNCHRONY Real-World study. Akero is headquartered in South San Francisco. Visit us at and follow us on  and  for more information.

Investor Contact:

Austin Murtagh

212.698.8696

Media Contact:

Sarah O’Connell

732.456.0092



EN
08/11/2023

Underlying

AKROAkero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akero Therapeutics

 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports Second Quarter 2025 Financial Results and P...

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marketable securities of $1,086.2 million at June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. ...

August 8, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global ...

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of...

June 3, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the Jefferies Global Healthcare Confe...

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at . Foll...

May 28, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025 SYMMETRY study results published in New England Journal of Medicine Raised $402.5 million in gross proceeds in a follow-on public offering...

May 12, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase...

Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025 Die Analyse der Ergebnisse zu EFX mit KI-basierter digitaler Pathologie unterstreicht den potenziellen Wert bei der Bewertung des histopathologischen Ansprechens Die Daten tragen dazu bei, dass die antifibrotische Wirkung von EFX bei Patienten mit präzirrhotischer MASH immer deutlicher wird SOUTH SAN FRANCISCO, Kalifornien, May 11, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein im klinischen Stadium tätiges Unternehmen, das ...

May 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch